ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
reversal factor · long-only model fund

Foundry Healthcare Long-Term Reversal Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FLRHHYPOTHETICAL MODEL
Since ’99
−36%
Expense Ratio
0.45%
placeholder
Holdings
82
cap-weighted
Inception
May 2019
placeholder
Full Sharpe
-0.02
Ann. Return (LS)
-0.3%
Ann. Volatility
17.7%
Max Drawdown
-77.5%
Test Sharpe ’19–26
-0.23
Test FF5 α (ann.)
-0.1%
vs Fama-French 5
Test FF5 α t-stat
-0.02
not significant
Monthly turnover
18%
of the long leg, per rebalance
Cumulative return (LS)
-36%
over 283 months
This fund holds the long leg only
Long leg Sharpe
0.52
what this fund holds
Long leg ann. return
11.1%
buyable, long-only
Long-short Sharpe
-0.02
requires shorting
Bottom bucket ann. return
11.3%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

283 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

82 of 82 · 100.0% of book
TickerCompanySectorMarket capWeight
1MRNA
MODERNA INCHealthcare$24.53B
22.92%
2SYRE
SPYRE THERAPEUTICS INCHealthcare$8.70B
8.13%
3ERAS
ERASCA INCHealthcare$5.96B
5.57%
4TXG
10X GENOMICS INCHealthcare$5.55B
5.19%
5DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
4.51%
6RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
3.56%
7KOD
KODIAK SCIENCES INCHealthcare$2.67B
2.49%
8ATAI
ATAIBECKLEY INCHealthcare$2.66B
2.48%
9NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
2.15%
10PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
2.11%
11NEOG
NEOGEN CORPHealthcare$2.24B
2.09%
12IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
2.09%
13AGL
AGILON HEALTH INCHealthcare$2.17B
2.02%
14DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
1.81%
15MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
1.75%
16NVCR
NOVOCURE LTDHealthcare$1.84B
1.72%
17TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
1.60%
18TDOC
TELADOC HEALTH INCHealthcare$1.70B
1.59%
19CMPS
COMPASS PATHWAYS PLCHealthcare$1.67B
1.56%
20VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
1.49%
21NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
1.48%
22NVAX
NOVAVAX INCHealthcare$1.35B
1.26%
23STAA
STAAR SURGICAL COHealthcare$1.32B
1.23%
24ABSI
ABSCI CORPHealthcare$1.29B
1.21%
25JBIO
JADE BIOSCIENCES INCHealthcare$1.03B
0.96%
26AVTX
AVALO THERAPEUTICS INCHealthcare$1.02B
0.95%
27FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.93%
28VOR
VOR BIOPHARMA INCHealthcare$980M
0.92%
29ANNX
ANNEXON INCHealthcare$950M
0.89%
30SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.80%
31ACRS
ACLARIS THERAPEUTICS INCHealthcare$793M
0.74%
32NGNE
NEUROGENE INCHealthcare$590M
0.55%
33STTK
SHATTUCK LABS INCHealthcare$577M
0.54%
34FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.54%
35RLMD
RELMADA THERAPEUTICS INCHealthcare$550M
0.51%
36VSTM
VERASTEM INCHealthcare$530M
0.50%
37CTEV
CLARITEV CORPHealthcare$518M
0.48%
38ZURA
ZURA BIO LTDHealthcare$518M
0.48%
39ARVN
ARVINAS INCHealthcare$517M
0.48%
40DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.48%
41PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.42%
42TENX
TENAX THERAPEUTICS INCHealthcare$420M
0.39%
43CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.38%
44EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.37%
45STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.36%
46ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.34%
47LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.29%
48SGHT
SIGHT SCIENCES INCHealthcare$274M
0.26%
49ZSQR
Z SQUARED INCHealthcare$260M
0.24%
50QTTB
Q32 BIO INCHealthcare$255M
0.24%
51SRZN
SURROZEN INCHealthcare$255M
0.24%
52RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.23%
53KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.20%
54SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.20%
55AGEN
AGENUS INCHealthcare$209M
0.19%
56IMUX
IMMUNIC INCHealthcare$207M
0.19%
57BDSX
BIODESIX INCHealthcare$204M
0.19%
58DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.19%
59AMWL
AMERICAN WELL CORPHealthcare$199M
0.19%
60TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.19%
61INGN
INOGEN INCHealthcare$178M
0.17%
62KRRO
KORRO BIO INCHealthcare$177M
0.17%
63OWLT
OWLET INCHealthcare$162M
0.15%
64JYNT
JOINT CORPHealthcare$127M
0.12%
65CUE
CUE BIOPHARMA INCHealthcare$126M
0.12%
66SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.11%
67VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.09%
68LIXT
LIXTE BIOTECHNOLOGY HOLDINGS INCHealthcare$91M
0.08%
69RLYB
RALLYBIO CORPHealthcare$87M
0.08%
70FRMM
FORUM MARKETS INCHealthcare$83M
0.08%
71PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.07%
72ACET
ADICET BIO INCHealthcare$76M
0.07%
73ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.07%
74CLNN
CLENE INCHealthcare$76M
0.07%
75NMAD
NOMAD POWER SOLUTIONS INCHealthcare$72M
0.07%
76SCLX
SCILEX HOLDING COHealthcare$72M
0.07%
77AGPU
AXE COMPUTE INCHealthcare$72M
0.07%
78LONA
LEONABIO INCHealthcare$68M
0.06%
79IMA
IMAGENEBIO INCHealthcare$61M
0.06%
80EDSA
EDESA BIOTECH INCHealthcare$59M
0.05%
81MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.05%
82TIL
INSTIL BIO INCHealthcare$50M
0.05%

Full long-leg book as of July 2026 · cap-weighted · total market cap $107.04B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

82 classified
Value
Blend
Growth
Large
Mid
Small
26%2
13%2
10%2
8%5
11%7
10%5
8%29
3%10
1%5

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 71% toward Large, 38% toward Growth. +10% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt71% → Large
SmallLarge
Value ↔ growth tilt38% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 2002July 2026; the right-hand end is the same value as the box’s dot. 82 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 82 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.7 (95% CI 0.9-1.9)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
15.4%
99% / 20d
Reference
9.3%
FF5 market (mkt)

historical method · 283 monthly observations · about 2.8 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.65x
within
parametric
1.44x
within
cornish fisher
1.29x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 19%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 1985
Entirely since publication
All 283 months of our record post-date the 1985 paper.
Sharpe -0.02-0.3% p.a.January 2003July 2026

There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

22 windows
Positive windows
59%
13 of 22 3-year windows made money
Worst window
-1.15
Sharpe, January 2018 – December 2020
January 2003July 2026
Median Sharpe
0.10
Dispersion
0.53
Best window
1.10

3-year rolling windows, stepping 1 year (22 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 2003
Trailing
PeriodLong legLong-short
1 yearcum.94.9%47.6%
3 yearsp.a.13.9%-3.6%
5 yearsp.a.2.9%-1.8%
10 yearsp.a.4.4%-5.2%
Since inceptionp.a.9.2%-1.8%
Calendar years
YearLong legLong-short
20267 mo31.0%26.8%
202526.0%-3.3%
2024-11.5%-21.4%
2023-3.3%-27.0%
2022-5.4%47.7%
2021-10.5%-13.8%
2020-4.6%-33.9%
201913.9%-9.7%
2018-18.8%-22.7%
201751.4%35.8%
2016-10.5%13.9%
201512.4%-2.5%
201433.4%3.8%
201367.3%9.8%
201220.9%-7.0%
201112.6%15.3%
20104.7%5.1%
200915.6%1.2%
2008-19.3%4.2%
20073.0%-0.6%
20066.7%7.4%
20056.4%-11.0%
20047.5%-8.3%
200332.1%-12.3%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FLRH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-05-17 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$107.04B

Methodology

The Foundry Healthcare Long-Term Reversal Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Long-Term Reversal signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.